Plant ID: NPO2438
Plant Latin Name: Euryale ferox
Taxonomy Genus: Euryale
Taxonomy Family: Nymphaeaceae
NCBI TaxonomyDB:
4414
Plant-of-the-World-Online:
605350-1
Analgesic; Aphrodisiac; Astringent; Deobstruent; Oxytoxic; Tonic
Bangladesh; South Africa; India; China; Japan; Taiwan; Russia
ADORA3; ADORA2A; ADORA1; | |
CDA; RECQL; TK1; ADK; GDA; | |
ACHE; | |
STAT6; | |
SLC28A2; SLC28A1; SLC28A3; | |
MAPT; LMNA; | |
SMN1;SMN2; |
Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Enzyme_unclassified | GDA | Guanine deaminase | Q9Y2T3 | CHEMBL3129 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.977E-08 | 8.612E-05 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 4.741E-08 | 1.475E-04 | ADORA1, ADORA2A, ADORA3 |
CC | GO:0044464; cell part | GO:0030673; axolemma | 3.148E-07 | 8.570E-04 | ADORA1, ADORA2A, MAPT |
BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 7.290E-07 | 1.221E-03 | SLC28A2, SLC28A3 |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 7.290E-07 | 1.221E-03 | SLC28A1, SLC28A3 |
MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 7.290E-07 | 1.221E-03 | SLC28A2, SLC28A3 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 2.186E-06 | 2.380E-03 | SLC28A1, SLC28A3 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 2.186E-06 | 2.380E-03 | SLC28A1, SLC28A3 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 2.186E-06 | 2.380E-03 | ADORA1, ADORA2A |
BP | GO:0032501; multicellular organismal process | GO:0007399; nervous system development | 6.751E-06 | 5.880E-03 | ACHE, ADORA1, GDA, SMN1, SMN2 |
CC | GO:0044456; synapse part | GO:0099055; integral component of postsynaptic membrane | 2.615E-05 | 1.424E-02 | ADORA1, ADORA2A |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.069E-05 | 1.630E-02 | ACHE, ADORA2A, CDA, MAPT, SMN1, SMN2, STAT6, TK1 |
CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 4.787E-05 | 2.266E-02 | SMN1, SMN2 |
CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 5.654E-05 | 2.620E-02 | SMN1, SMN2 |
MF | GO:0003824; catalytic activity | GO:0019206; nucleoside kinase activity | 6.593E-05 | 2.761E-02 | ADK, TK1 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 6.885E-04 | 1.928E-02 | CDA, TK1 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.548E-03 | 2.167E-02 | ADORA2A, ADORA3, ADORA1 |
09100 Metabolism | 09104 Nucleotide metabolism | hsa00240 | Pyrimidine metabolism | 3.527E-03 | 3.204E-02 | CDA, TK1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 4.578E-03 | 3.204E-02 | ADORA3, ADORA1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 8.681E-03 | 3.841E-02 | ADORA3, ADORA1 |
09120 Genetic Information Processing | 09122 Translation | hsa03013 | RNA transport | 9.187E-03 | 3.841E-02 | SMN2, SMN1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.214E-02 | 4.250E-02 | ADORA2A, ADORA1 |
09100 Metabolism | 09104 Nucleotide metabolism | hsa00230 | Purine metabolism | 9.602E-03 | 3.841E-02 | GDA, ADK |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.822E-02 | 5.669E-02 | CDA, GDA, ADK, TK1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 4.657E-02 | 1.257E-01 | ADORA1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TK1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; MAPT; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TK1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
C00-D49: Neoplasms | Cancer | C00-C96 | TK1; ADORA3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TK1; CDA; |
NA: NA | Hepatitis C virus infection | NA | ADORA3; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
C00-D49: Neoplasms | Prostate cancer | C61 | TK1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TK1; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; ADK; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1; |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |